Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pop Parliament TRIPS up Pro-industry agreements, dampens emerging markets

This article was originally published in Scrip

Executive Summary

Flushed from their success in blocking the Anti-Counterfeiting Trade Agreement (ACTA), key political groups from the European Parliament's are now turning their attention to other EU trade agreements that might threaten access to medicines in emerging markets and developing countries. Representatives of three separate European parliamentary groups have told Scrip that they would be looking out for anything in European Commission proposals on trade that might limit poorer nations' access to healthcare products, including so-called TRIPS Plus measures.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC018306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel